AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03965377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Safety Hero Computer Game
Description: Home Safety Hero computer game presents players with virtual rooms in a home where vilians have planted safety risks. It involves the player taking the role of a body guard for a child. It has three phases: 1. Identifying risks in a set of rooms (e.g., burn, falling, suffocation, poisoning); 2. Identifying risks and then selecting a resolution to reduce the risk or eliminate it entirely; and 3. Identifying risk when faced with distractions typical to home environments (e.g., phone ringing, fire engine siren sounds, a moving child).
Study NCT00594217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral micronized progesterone suspension
Description: oral micronized progesterone suspension, single 100 mg oral dose
Study NCT00594217 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
Study NCT03209284 — intervention group
Intervention type: PROCEDURE
Intervention: transcrestal sinus floor elevation
Description: augmentation procedure with xenograft
Study NCT03611439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ReBuilder
Description: 8-component botanical dietary supplement
Study NCT01566396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A3F
Description: A3F fractional RF treatments for facial wrinkles
Study NCT01864174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Study NCT03611439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Placebo Capsule
Study NCT00355316 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Study NCT00355316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Study NCT03784183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation (CS)
Description: CS consists of a wide range of structured activities aimed at the general improvement of social functioning and the maintenance of different cognitive functions. It is a non-specific in-group approach that places particular emphasis on social interactions.
Study NCT00245271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS103HP
Description: Maximum of 13 bags of OMS103HP irrigation solution over a maximum of 2 hours
Study NCT00245271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Maximum of 13 bags of BSS irrigation over a maximum of 2 hours.
Study NCT01864174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin IR
Study NCT01864174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching with Metformin XR
Study NCT02317549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB1148
Study NCT02317549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02410343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-1106
Description: A starting dose of 5.0 mg was expected to be appropriate for most patients because the daily recommended starting dose of recombinant human growth hormone (rhGH) treatments (e.g. somatropin) is 0.2 mg/day, and the conversion factor was 28. Dosage could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 until the participant's insulin-like growth factor 1 (IGF-1) standard deviation score (SDS) was within the range of -0.5 to +1.5.
Study NCT02410343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment was administered in a blinded fashion and titrated on weeks 4, 8, 12 and 16 to mimic the active treatment.
Study NCT02072616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pancreatic adenocarcinoma diagnosis
Study NCT00087802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine/Eloxatin (GEMOX)
Description: GEMOX \[gemcitabine/Eloxatin™ (Oxaliplatin) - 21 day cycle\] Gemcitabine 1000 mg/m2 will be administered over 30 minutes on Days 1 and 8 and Eloxatin™ 130 mg/m2 will be administered over 2 hours on Day 1, after gemcitabine administration, every 21 days \[3-week cycle\]
Study NCT01864174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching with Metformin IR
Study NCT02739997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
Description: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
Study NCT02739997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole 500 mg
Description: metronidazole 500 mg administered as an IV infusion
Study NCT00816504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galactose
Description: Oral galactose, 0.2 g/kg/dose twice daily for 28 days
Study NCT02290171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity groups
Description: Children attend to activity groups weekly during the intervention periode.
Study NCT02290171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group based dietary counselling
Description: Parents attend to four sessions of group based dietary counselling
Study NCT02290171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual counselling
Description: Parents attend to individual counselling focusing on parental skills and family structure
Study NCT00887263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 3 mg TID
Study NCT00887263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg TID
Study NCT01769183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Squalamine Lactate ophthalmic solution 0.2%
Description: Patients will start with Squalamine one drop twice daily to the affected eye. If at one week the neovascularization shows no sign of regression, then the dose will be doubled to four times daily with a follow up at one day and one week following the increased dose frequency, then resuming the schedule at four weeks. If neovascularization returns within the study, the dose will be doubled to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Squalamine treatment will discontinue after the week 20 visit.
Study NCT04682145 — intervention group
Intervention type: DRUG
Intervention: Turoctocog alfa pegol
Description: Patients will be treated with commercially available turoctocog alfa pegol according to routine clinical practice at the discretion of the treating physician. A decision to initiate treatment with commercially available turoctocog alfa pegol has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in the registry in scope.
Study NCT00267592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: Talampanel administered orally TID beginning the first day and continued until there is talampanel-related toxicity or tumor progression.
Study NCT00267592 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT) 5 days a week +
Study NCT00267592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide(TMZ) 75mg
Description: temozolomide(TMZ) 75mg 3 times daily (TID) for 6 weeks
Study NCT00267592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant TMZ 200mg
Description: adjuvant TMZ 200mg TID for 5 consecutive days each month for a total of 6 months.
Study NCT01732172 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sperm sample
Description: Sperm sample
Study NCT01732172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sperm sample
Description: Sperm sample
Study NCT00155545 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Motion analysis of patients
Study NCT00857623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2066
Description: Capsule, once daily, 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28.
Study NCT00857623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, once daily
Study NCT04759885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II: NTC015 low dose
Description: Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
Study NCT00087802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin/paclitaxel (CP)
Description: CP \[carboplatin/paclitaxel - 21 day cycle\]~o Paclitaxel 225 mg/m2 will be administered over 3 hours on Day 1 followed by carboplatin at a dose calculated to produce an area under the concentration-time curve (AUC) of 6.0 over 30-60 minutes on Day 1 every 21 days \[3-week cycle\]
Study NCT04759885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II: NTC015 medium dose
Description: Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
Study NCT04759885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II: NTC015 high dose
Description: Participants should self administer the preparation within 60 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
Study NCT04759885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase III: NTC015 selected dose
Description: Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
Study NCT04759885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phase III: Polyethylene glycol plus ascorbate solution (2L PEG ASC)
Description: The instructions for product administration are followed according to the Summary of Product Characteristics.~One treatment consists of two litres of Moviprep® taken according to split-dose regimen.~The first litre of Moviprep® is prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution. The reconstituted solution must be drunk over a period of one to two hours the evening before colonoscopy. About half a litre of clear liquid should be drunk in the next hour to prevent dehydration according to local practice at the centre. This process should be repeated with a second litre of Moviprep® prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution in the early morning of the day of the procedure.
Study NCT03141047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifespan Integration
Description: A protocol based psychological treatment method
Study NCT03384602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dalcroze Eurhythmics Program
Description: music-based multi-task exercise in group setting
Study NCT03384602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home exercise strength program
Description: simple strength exercise program to perform individually at home
Study NCT01799083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: A continuous 5-day lower-dose decitabine transfusion will be performed for patients during each treatment cycle, and autologous cytokine-induced killer cells may be transfused or chemotherapy may be also added.
Study NCT01799083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cytokine-induced killer cell
Description: Autologous cytokine-induced killer cells may be used for patients before and after decitabine treatment.
Study NCT00888355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: losartan tablet (MK0954) 25 or 50 mg q.a.m. or 25 mg b.i.d., for 12 weeks
Study NCT00888355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo to losartan tablet q.a.m. , for 12 weeks
Study NCT00085280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT00085280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03062657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRESTIGE LP™ Cervical Disc
Description: The PRESTIGE LP™ Cervical Disc is an artificial cervical disc comprising of two low-profile metal plates that interface through a ball and trough mechanism, permitting segmental spinal motion. The PRESTIGE LP™ Cervical Disc was approved by the Food and Drug Administration (FDA) to be used at a single and two contiguous levels.
Study NCT03403192 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EZ-Blocker
Description: The EZ-Blocker essentially functions as a bronchial blocker with a 7-Fr shaft with two separate occlusive balloons coming off this shaft in a Y configuration designed to rest on the carina. Once anchored in place the operator can choose to inflate one of the two occlusive balloons to isolate one main stem bronchus or the other. According to the manufactures recommendations the EZ-blocker is placed through a Y-piece adaptor included with the blocker kit. A flexible fiberoptic bronchoscope (FFB) is placed in a separate limb of this Y-piece and this fed through along side the EZ-blocker to visualize and confirm placement of the of the BB. The balloon is then inflated typically under direct vision to occlude that bronchus thus isolating that lung hopefully achieving full lung isolation.
Study NCT03403192 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DLT
Description: A Double Lumen Tube (DLT) is made of two small-lumen endotracheal tubes of unequal length fixed side by side. The shorter tube ends in the trachea while the longer tube is placed in either the right or left bronchus to ventilate the right or left lung.
Study NCT03603652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation
Description: Ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon. Prior to the ablation, the treating physician will perform an endobronchial ultrasound to confirm disease staging.
Study NCT03566940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV
Description: Participants will receive 0.5 milliliter (mL) of sIPV as a solution for IM injection.
Study NCT03566940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cIPV
Description: Participants will receive 0.5 mL of cIPV as a suspension for IM injection.
Study NCT03566940 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cIPV
Description: Participants will receive 0.5 mL of cIPV as a suspension for IM injection.
Study NCT02660099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavior Therapy
Description: The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet platform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks. Both parents and adolescents are involved in treatment. Parents will also receive three lectures on 1, Autism spectrum disorder, 2, CBT and functional analysis and 3, Parental strategies
Study NCT02572167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg by intravenous (IV) infusion for up to 4 cycles
Study NCT02572167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: 3 mg/kg by intravenous (IV) infusion for up to 4 cycles
Study NCT03923374 — intervention group
Intervention type: DRUG
Intervention: Subutex / Buprenorphine
Description: Pregnant Mothers must be taking buprenorphine / subutex for opioid use disorder.
Study NCT03923374 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal & Neonatal MRI
Description: Mothers who consent will be given a fetal MRI and after the baby is born, a neonatal MRI.
Study NCT03923374 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DNA/Genetic/Pharmacokenetic Blood Draws
Description: Throughout the pregnancy, Mothers will be participating in blood collection throughout the study. At enrollment, we will collect DNA, Genetic and PK blood specimens, then throughout the study, we will be collecting random PK samples.
Study NCT03325985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led telephonic case management
Description: Telephonic meetings with a palliative care nurse. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
Study NCT03325985 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated,outpatient specialty palliative care
Description: In-person or telehealth palliative care visits with a palliative care provider. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
Study NCT01471990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pituitary Adenylate Cyclase-Activating Polypeptide-38
Description: 10 pmol/kg/min over 20 mins
Study NCT01471990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasoactive Intestinal Peptide
Description: 8 pmol/kg/min over 20 mins
Study NCT00649688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg
Description: 100/50mg, single dose fasting
Study NCT00649688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopressor HCT® Tablets 100/50 mg
Description: 100/50mg, single dose fasting
Study NCT05722301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Therapy
Description: The testosterone pellet implantation will be performed 2 weeks before surgery. The dose is determined by baseline levels of sex hormone binding globulin (SHBG) in the following manner: If SHBG > 60nmol/L implant 5 Testosterone Compounded 200mg (total 1000mgs testosterone). If SHBG 41-59 nmol/L implant 4 Testosterone Compounded 200mg (total 800mgs testosterone). If SHBG \<40 nmol/L implant 3 Testosterone Compounded 200mg (total 600mgs testosterone).
Study NCT02578953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride-Test product
Description: Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by GSK, Poznan.
Study NCT02578953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride-Reference product
Description: Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Glycerin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by Catalent, Beinheim.
Study NCT05722301 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Testosterone Therapy
Description: For the sham procedure no pellets will be implanted.
Study NCT00580840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab pegol
Description: 400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks)
Study NCT03014232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLED-f with HCO dialyzer
Description: Online SLED-f with high cut-off dialyzers were performed using the Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). Super-flux, Sureflux 150FH (Nipro Corporation, Osaka, Japan; cellulose triacetate material, pore size 78 A◦, Kuf 66.9 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
Study NCT03014232 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SLED-f with HF dialyzer
Description: Online SLED-f with standard high-flux dialyzers were performed using the same Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). High-flux ELISIO 150H (Nipro Corporation, Osaka, Japan; polynephron material, pore size 50-60 A◦, Kuf 67 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
Study NCT03541421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient involvement in administration of drugs
Description: The patient´s own drugs and an updated medication list will be placed in a lockable bedside table. During hospitalization the patient is responsible for taking his own medication. If a new drug is prescribed, the patient will be involved and instructed about it. Furthermore the smallest package will be delivered so that the patient can begin self-administration of the new drug during hospitalization.